Cefepime: Indications, Dosing, Renal Adjustments, Duration, and Monitoring
FDA-Approved Indications
Cefepime is indicated for moderate to severe infections including pneumonia, febrile neutropenia, urinary tract infections, skin/soft tissue infections, and complicated intra-abdominal infections (with metronidazole). 1
Specific Indications and Standard Dosing (CrCL >60 mL/min):
- Moderate to severe pneumonia (S. pneumoniae, P. aeruginosa, K. pneumoniae, Enterobacter): 1-2 g IV every 8-12 hours for 10 days
- Febrile neutropenia: 2 g IV every 8 hours for 7 days (or until neutropenia resolves)
- Mild-moderate UTI/pyelonephritis: 0.5-1 g IV every 12 hours for 7-10 days
- Severe UTI/pyelonephritis: 2 g IV every 12 hours for 10 days
- Skin/soft tissue infections: 2 g IV every 12 hours for 10 days
- Complicated intra-abdominal infections (with metronidazole): 2 g IV every 8-12 hours for 7-10 days 1
For P. aeruginosa infections specifically, use 2 g IV every 8 hours. 1
Administration
Administer cefepime intravenously over approximately 30 minutes. 1
Critical Care Considerations:
In ICU patients with preserved renal function, higher doses than standard are recommended initially, pending therapeutic drug monitoring (TDM). 2 The French critical care guidelines suggest doses of cefepime greater than 4 g/day may be required to achieve pharmacokinetic/pharmacodynamic targets for bacteria with high MICs, particularly P. aeruginosa 2.
For infections with high MIC organisms, consider prolonged or continuous infusions to increase the probability of achieving PK-PD targets. 2 Recent data supports a reduced-dose continuous infusion regimen of 2 g loading dose followed by 4 g/day continuous infusion, which achieved 96% target attainment for Enterobacterales and 93% for P. aeruginosa with favorable neurotoxicity profile 3.
Renal Dose Adjustments
Dose adjustment is mandatory for CrCL ≤60 mL/min to prevent neurotoxicity. 1
Dosing by Creatinine Clearance:
| CrCL (mL/min) | Recommended Maintenance Dose |
|---|---|
| >60 | Standard dosing (see above) |
| 30-60 | Reduce frequency to every 24 hours (or 2 g every 12 hours for severe infections) |
| 11-29 | 500 mg-2 g every 24 hours (depending on infection severity) |
| <11 | 250 mg-1 g every 24 hours |
| Hemodialysis | 1 g on day 1, then 500 mg every 24 hours (1 g every 24 hours for febrile neutropenia); administer AFTER dialysis |
| CAPD | Every 48 hours dosing |
Use the Cockcroft-Gault equation to estimate creatinine clearance when only serum creatinine is available. 1
Critical Pitfall:
Most cases of cefepime-induced neurotoxicity occur in patients with renal impairment who never received appropriate dose adjustment. 4 A systematic review found that most patients experiencing neurotoxicity were receiving either 2 g every 12 hours or 2 g every 8 hours despite renal dysfunction 4.
Neurotoxicity Monitoring
Cefepime has significant neurotoxic potential, particularly in patients ≥65 years old and those with renal impairment. 2, 4, 5, 6
Key Neurotoxicity Thresholds:
- Cefepime trough >22 mg/L (intermittent dosing) or steady-state >35 mg/L (continuous infusion) associated with 50% risk of neurotoxicity 2
- Free drug concentration >8× MIC increases neurotoxicity risk without additional benefit 2
- Cefepime has relatively high pro-convulsive activity (160 relative to penicillin G = 100) 2
Clinical Manifestations:
Neurotoxicity typically presents as acute confusional state, encephalopathy, myoclonus, seizures, or status epilepticus. Most cases occur between days 2-5 of therapy, with resolution typically within 1-5 days after discontinuation or dose adjustment. 4
Monitoring Strategy:
For high-risk patients (age ≥65, renal impairment, high doses, continuous infusion), perform therapeutic drug monitoring within 24-48 hours of treatment initiation. 5 When TDM results were obtained ≤48 hours, only 24% of overexposed patients developed neurotoxicity compared to 57.4% when results were delayed >48 hours 5.
Target trough concentrations <20 mg/L for safety when aiming for 50% fT>MIC, or <35 mg/L when targeting 100% fT>MIC. 7
Monitor for unexplained neurological changes and consider temporary suspension of cefepime if neurotoxicity is suspected. 2
Special Populations
Augmented Renal Clearance (ARC):
Patients with CrCL >150 mL/min may require standard or higher doses without adjustment. In trauma and brain-injured ICU patients with ARC receiving 6 g/day continuous infusion, only 32% experienced overexposure compared to 87.5% in those with mild renal impairment 5. Age >33 years was a risk factor for overexposure even in ARC patients 5.
Renal Replacement Therapy:
For patients on intermittent hemodialysis, use 1 g on day 1, then 500-1 g every 24 hours administered AFTER dialysis (approximately 68% removed during 3-hour dialysis) 1. Recent data in P. aeruginosa infections showed 72.7% 30-day survival with median dose of 1000 mg every 24 hours in intermittent hemodialysis 8.
For continuous venovenous hemofiltration, 2000 mg every 12 hours achieved good outcomes in P. aeruginosa infections. 8
Pediatric Dosing (2 months to 16 years, ≤40 kg):
- 50 mg/kg every 12 hours for most infections
- 50 mg/kg every 8 hours for moderate-severe P. aeruginosa pneumonia or febrile neutropenia
- Maximum dose should not exceed adult dosing 1
Treatment Duration
Standard durations range from 7-10 days depending on infection type and clinical response. 1
- Pneumonia: 10 days
- Febrile neutropenia: 7 days or until neutropenia resolves
- UTI/pyelonephritis: 7-10 days
- Skin/soft tissue: 10 days
- Intra-abdominal: 7-10 days
Re-evaluate need for continued therapy frequently in patients whose fever resolves but remain neutropenic beyond 7 days. 1
Antimicrobial Stewardship Considerations
Despite validated indications, only 13.4% of cefepime prescriptions meet all criteria for proper use. 9 Key deficiencies include inadequate reassessment at 48-72 hours (44.2% compliance) and at 7-10 days (60.9% compliance) 9.
Cefepime is a carbapenem-sparing agent due to stability against AmpC β-lactamases, making it valuable for CESP group organisms (Citrobacter, Enterobacter, Serratia, Providencia) and P. aeruginosa. 9, 10